AKT1 and medulloblastoma: Taking advantage of the novel, highly specific, clinical grade Pan-PI3K inhibitor GDC-0941 [18], we confirm that PI3K/AKT signalling is indeed a critical target for anti-cancer therapy in human medulloblastoma.